Cargando…
Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
Cancer immunotherapy was selected as the Breakthrough of the Year 2013 by the editors of Science, in part because of the successful treatment of refractory hematological malignancies with adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells. Effective treatment of B cell leukemia...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544486/ https://www.ncbi.nlm.nih.gov/pubmed/25859858 http://dx.doi.org/10.1007/s40259-015-0122-9 |